NEWS

For our visitors who seek the latest industry news and updates to keep abreast with the goings-on of the business on a global scale, Pharmaceutical Industry portal grants a dynamic and diverse feed of news items.

news

In a classic David Vs Goliath case, the US-based drugmaker Gilead that has made billions of dollars over its blockbuster range of Hepatitis C drugs is facing an unconventional challenger. Beacon Pharma, a little known Bangladeshi drugmaker, has emerged as the David to the Goliath that Gilead is. Beacon has…

news

The U.S. Food and Drug Administration has enhanced warnings of side effects of a group of strong antibiotics used to treat a variety of respiratory and urinary tract infections and limited their use to patients with no alternatives. The antibiotics known as fluoroquinolones include Johnson & Johnson's Levaquin, Bayer's Cipro…

news

Lupin, India's third-largest drugmaker, is in talks with Japan's Astellas and Shionogi to buy the off-patent medicine brands they have separately put on the block, two people aware of the development said. The basket of drugs that Astellas and Shionogi are divesting could fetch each company about $100 million, the…

news

Seoul Pharma Co., Ltd Says it signs contract with Thitiratsanon Co.,Ltd, to provide medicine in Thailand, with a term of five years. Says the contract worth $5.5 million(6.22 billion won).   Source : reuters.com

news

An off-patent malaria drug could help to destroy cancer cells by making them more susceptible to radiotherapy, according to early work that has prompted British scientists to start a clinical trial. Researchers reported on Monday that atovaquone boosted oxygen levels in tumor cells in mice, making radiotherapy more effective against…

news

Alnylam Pharmaceuticals Inc Company updates guidance for phase 3, and now plans to start studies in early 2017. Plans to report additional data from fitusiran studies in late 2016. Alnylam announces new positive interim phase 1 study results for fitusiran, a once-monthly, subcutaneous, investigational rnai therapeutic targeting antithrombin for the…

news

Biocon's contract research arm Syngene International has lined up $200 million (around Rs 1,342 crore) capex to bolster its manufacturing capabilities over the next three years. The company plans to invest $100 million (around Rs 665.27 crore) in a greenfield facility at Mangalore, the first phase of which would be…

news

Nanjing Pharmaceutical Co., Ltd. Says it completes 2016 first tranche private debt financing instruments worth 100 million yuan. Says the instruments with a term of three months and rate of 3.8 percent.   Source : reuters.com

news

China health authorities have started a nationwide inspection of vaccinations four months after a scandal broke involving nearly $90 million worth of illegal vaccines that were suspected of being sold in dozens of provinces. Authorities will track purchases as well as the distribution of vaccines and vaccination records, to ensure…

news

Scientists are opening a new front in the war on cancer with plans to develop "anti-evolution" drugs to stop tumor cells from developing resistance to treatment. Britain's Institute of Cancer Research (ICR), one of the world's top cancer centers, said on Friday its initiative was the first to have at…